NASDAQ:LPCN - Lipocine News Headlines

Sign in or create an account to add this stock to your watchlist.
$2.20 +0.03 (+1.38 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$2.20
Today's Range$2.10 - $2.22
52-Week Range$1.03 - $2.64
Volume200,170 shs
Average Volume604,988 shs
Market Capitalization$52.54 million
P/E Ratio-4.00
Dividend YieldN/A
Beta0.68

Headlines

Lipocine (NASDAQ LPCN) News Headlines

Source:
DateHeadline
Lipocine to Participate at the ROTH Battle of the NASH Thrones Spring Investor Conference - PRNewswireLipocine to Participate at the ROTH Battle of the NASH Thrones Spring Investor Conference - PRNewswire
www.prnewswire.com - March 21 at 8:58 AM
Lipocine to Participate at the ROTH Battle of the NASH Thrones Spring Investor ConferenceLipocine to Participate at the ROTH Battle of the NASH Thrones Spring Investor Conference
finance.yahoo.com - March 21 at 8:58 AM
Lipocine Inc (LPCN) PT Raised to $5 at HC Wainwright on Incremental NASH Value Contribution - StreetInsider.comLipocine Inc (LPCN) PT Raised to $5 at HC Wainwright on Incremental NASH Value Contribution - StreetInsider.com
www.streetinsider.com - March 14 at 7:20 PM
LPCN: NASH ToplineLPCN: NASH Topline
finance.yahoo.com - March 14 at 7:20 PM
Lipocine Announces Presentation Highlighting Therapeutic Potential of LPCN 1144 in NAFLD and NASH Selected for ENDO 2019Lipocine Announces Presentation Highlighting Therapeutic Potential of LPCN 1144 in NAFLD and NASH Selected for ENDO 2019
finance.yahoo.com - March 14 at 8:28 AM
Lipocine Inc.Lipocine Inc.
www.barrons.com - March 12 at 10:48 PM
Lipocine Surges On Positive 16-Week Liver Imaging Study For Its NASH CandidateLipocine Surges On Positive 16-Week Liver Imaging Study For Its NASH Candidate
finance.yahoo.com - March 12 at 10:48 PM
Lipocine to Participate at the 31st Annual ROTH ConferenceLipocine to Participate at the 31st Annual ROTH Conference
www.marketwatch.com - March 12 at 8:32 AM
Lipocine up 29% premarket on positive data on NASH candidate LPCN 1144Lipocine up 29% premarket on positive data on NASH candidate LPCN 1144
seekingalpha.com - March 12 at 8:32 AM
Lipocines LPCN 1144 for NASH Demonstrates Substantial Fatty Liver Resolution and Meaningful Liver Fat Reduction in NAFLD PopulationLipocine's LPCN 1144 for NASH Demonstrates Substantial Fatty Liver Resolution and Meaningful Liver Fat Reduction in NAFLD Population
finance.yahoo.com - March 12 at 8:32 AM
Lipocine Inc (LPCN) Expected to Post Earnings of -$0.11 Per ShareLipocine Inc (LPCN) Expected to Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - March 12 at 4:21 AM
Lipocine to Participate at the 31st Annual ROTH Conference - PRNewswireLipocine to Participate at the 31st Annual ROTH Conference - PRNewswire
www.prnewswire.com - March 11 at 7:42 PM
HC Wainwright Reaffirms Buy Rating for Lipocine (LPCN)HC Wainwright Reaffirms Buy Rating for Lipocine (LPCN)
www.americanbankingnews.com - March 11 at 9:41 AM
Lipocine (LPCN) Releases Quarterly  Earnings Results, Misses Estimates By $0.02 EPSLipocine (LPCN) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - March 7 at 11:11 AM
Lipocine Announces Financial and Operational Results for the Year Ended December 31, 2018Lipocine Announces Financial and Operational Results for the Year Ended December 31, 2018
finance.yahoo.com - March 6 at 7:33 PM
Does Lipocine Inc.’s (NASDAQ:LPCN) CEO Pay Reflect Performance?Does Lipocine Inc.’s (NASDAQ:LPCN) CEO Pay Reflect Performance?
finance.yahoo.com - February 26 at 6:43 PM
Lipocine on go with mid-stage study of LPCN 1144 in NASHLipocine on go with mid-stage study of LPCN 1144 in NASH
seekingalpha.com - February 14 at 6:25 PM
Lipocine Inc. Announces FDA Clearance of IND to Commence Phase 2 Study of LPCN 1144 in Biopsy Confirmed NASH SubjectsLipocine Inc. Announces FDA Clearance of IND to Commence Phase 2 Study of LPCN 1144 in Biopsy Confirmed NASH Subjects
finance.yahoo.com - February 14 at 8:19 AM
LPCN: Soldiering on and Winning Some BattlesLPCN: Soldiering on and Winning Some Battles
finance.yahoo.com - January 25 at 6:12 PM
4 Healthcare Stocks Looking To Have A Strong Thursday (1/24/19)4 Healthcare Stocks Looking To Have A Strong Thursday (1/24/19)
finance.yahoo.com - January 24 at 6:33 PM
Lipocine Files IND To Evaluate LPCN 1144 In Biopsy Confirmed NASH SubjectsLipocine Files IND To Evaluate LPCN 1144 In Biopsy Confirmed NASH Subjects
finance.yahoo.com - January 24 at 8:17 AM
Form 8-K Lipocine Inc. For: Jan 17 - StreetInsider.comForm 8-K Lipocine Inc. For: Jan 17 - StreetInsider.com
www.streetinsider.com - January 18 at 5:45 PM
Lipocine's stock rockets on premarket leading volume after upbeat liver fat study resultsLipocine's stock rockets on premarket leading volume after upbeat liver fat study results
finance.yahoo.com - January 17 at 7:24 PM
Lipocines NASH Candidate Shows Promise In Liver Fat StudyLipocine's NASH Candidate Shows Promise In Liver Fat Study
finance.yahoo.com - January 17 at 7:24 PM
BRIEF-Lipocines NASH Candidate Achieves Meaningful Liver Fat Reduction Based On Interim ResultsBRIEF-Lipocine's NASH Candidate Achieves Meaningful Liver Fat Reduction Based On Interim Results
www.msn.com - January 17 at 8:24 AM
Lipocines LPCN 1144 shows positive action in liver fat study; shares up 125% premarketLipocine's LPCN 1144 shows positive action in liver fat study; shares up 125% premarket
seekingalpha.com - January 17 at 8:24 AM
Lipocines NASH Therapy Candidate Achieves Meaningful Liver Fat Reduction Based on Interim ResultsLipocine's NASH Therapy Candidate Achieves Meaningful Liver Fat Reduction Based on Interim Results
finance.yahoo.com - January 17 at 8:24 AM
Lipocine up 6% premarket on Tlando phlebotomy studyLipocine up 6% premarket on Tlando phlebotomy study
seekingalpha.com - December 31 at 5:18 PM
Lipocine Announces Successful Ex Vivo Conversion Assessment of TLANDO™Lipocine Announces Successful Ex Vivo Conversion Assessment of TLANDO™
finance.yahoo.com - December 31 at 8:20 AM
Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Presentation at 2019 NASH-TAG Conference - PRNewswireLipocine Announces LPCN 1144 Clinical Trial Results Selected for Presentation at 2019 NASH-TAG Conference - PRNewswire
www.prnewswire.com - December 23 at 8:15 AM
Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Presentation at 2019 NASH-TAG ConferenceLipocine Announces LPCN 1144 Clinical Trial Results Selected for Presentation at 2019 NASH-TAG Conference
finance.yahoo.com - December 21 at 8:21 AM
Lipocine Announces LPCN 1144 MRI-PDFF Clinical Results Selected for Presentation at Keystone Symposia on Integrated Pathways of Disease in NASH and NAFLDLipocine Announces LPCN 1144 MRI-PDFF Clinical Results Selected for Presentation at Keystone Symposia on Integrated Pathways of Disease in NASH and NAFLD
finance.yahoo.com - December 20 at 8:20 AM
LPCN: Tlando Readouts Coming Soon; NDA to FollowLPCN: Tlando Readouts Coming Soon; NDA to Follow
finance.yahoo.com - November 26 at 5:18 PM
Lipocine Inc (NASDAQ:LPCN): Are Analysts Optimistic?Lipocine Inc (NASDAQ:LPCN): Are Analysts Optimistic?
finance.yahoo.com - November 22 at 5:26 PM
Lipocine: 3Q Earnings SnapshotLipocine: 3Q Earnings Snapshot
finance.yahoo.com - November 7 at 5:47 PM
Lipocine Announces Financial and Operational Results for the Three and Nine Months Ended September 30, 2018Lipocine Announces Financial and Operational Results for the Three and Nine Months Ended September 30, 2018
finance.yahoo.com - November 7 at 8:19 AM
Lipocine Announces Completion of Enrollment in LPCN 1144 Liver Imaging Study in Subjects At-Risk for NASHLipocine Announces Completion of Enrollment in LPCN 1144 Liver Imaging Study in Subjects At-Risk for NASH
finance.yahoo.com - November 5 at 8:34 AM
Lipocine Announces Completion of Enrollment in Ambulatory Blood Pressure Study for TLANDO™Lipocine Announces Completion of Enrollment in Ambulatory Blood Pressure Study for TLANDO™
finance.yahoo.com - November 1 at 6:02 PM
LPCN: Androgen Therapy in NASH: A Comprehensive ApproachLPCN: Androgen Therapy in NASH: A Comprehensive Approach
finance.yahoo.com - October 29 at 5:02 PM
Lipocine (LPCN) Announces LPCN 1144 Clinical Trial Results Selected for Late-Breaker Presentation at AASLDLipocine (LPCN) Announces LPCN 1144 Clinical Trial Results Selected for Late-Breaker Presentation at AASLD
www.streetinsider.com - October 12 at 8:15 AM
Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Late-Breaker Presentation at The Liver Meeting ...Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Late-Breaker Presentation at The Liver Meeting ...
www.prnewswire.com - October 11 at 4:51 PM
Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Late-Breaker Presentation at The Liver Meeting® 2018Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Late-Breaker Presentation at The Liver Meeting® 2018
finance.yahoo.com - October 11 at 8:18 AM
Lipocine to Present at the Ladenburg Thalmann 2018 Healthcare ConferenceLipocine to Present at the Ladenburg Thalmann 2018 Healthcare Conference
finance.yahoo.com - September 25 at 8:14 AM
Do Institutions Own Shares In Lipocine Inc (NASDAQ:LPCN)?Do Institutions Own Shares In Lipocine Inc (NASDAQ:LPCN)?
finance.yahoo.com - September 19 at 5:41 PM
LPCN: 2Q:18 Operational and Financial ResultsLPCN: 2Q:18 Operational and Financial Results
finance.yahoo.com - August 29 at 4:58 PM
Lipocine: 2Q Earnings SnapshotLipocine: 2Q Earnings Snapshot
finance.yahoo.com - August 7 at 5:25 PM
Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2018Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2018
finance.yahoo.com - August 7 at 8:21 AM
Lipocine to Present at the Canaccord Genuity 38th Annual Growth ConferenceLipocine to Present at the Canaccord Genuity 38th Annual Growth Conference
finance.yahoo.com - August 2 at 8:20 AM
Lipocine commences ambulatory blood pressure study with Tlando; shares ahead 9% premarketLipocine commences ambulatory blood pressure study with Tlando; shares ahead 9% premarket
seekingalpha.com - June 7 at 5:24 PM
Lipocine Announces Dosing in Ambulatory Blood Pressure Study for TLANDO™Lipocine Announces Dosing in Ambulatory Blood Pressure Study for TLANDO™
finance.yahoo.com - June 7 at 8:17 AM
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel